- Home
- DFLI vs MDCX Comparison
DFLI vs MDCX Comparison
Compare DFLI & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DFLI | MDCX |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 17.1M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DFLI | MDCX |
|---|---|---|
| Price | $1.32 | $0.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.25 | ★ $14.50 |
| AVG Volume (30 Days) | 351.1K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.25 | $0.25 |
| 52 Week High | $5.15 | $3.05 |
Technical Indicators
Market Signals| Indicator | DFLI | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 49.44 |
| Support Level | $0.64 | $0.32 |
| Resistance Level | $2.24 | $0.36 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 60.53 | 50.33 |
Price Performance
Historical ComparisonAbout DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.